RGC.™

Regeneron Genetics Center

Regeneron Genetics Center (RGC) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics. The primary goal of RGC is to improve patient outcomes by identifying novel drug targets, clinical indications for development programs, and genomic biomarkers for pharmacogenomic applications.

Leadership Team

Gonçalo Abecasis, PhD
VP & Chief Genomics
and Data Science Officer

Aris Baras, MD, MBA
SVP & Head of
Regeneron Genetics Center

Michael Cantor, MD, MA
VP of Clinical Informatics

Giovanni Coppola, MD
VP of Neuroscience &
Ophthalmology Genetics

Andrew Deubler
VP & Chief Business
and Administrative Officer

Luca Lotta, MD, PhD
VP of Cardiovascular, Metabolic,
and Skeletal Genetics

John Overton, PhD
VP & Chief Sequencing Officer

Jeffrey Reid, PhD
VP & Chief Data Officer

Alan Shuldiner, MD
VP of Founder &
Special Populations

Katherine Siminovitch, MD
Executive Director,
Immunology Genetics

"RGC applies the best and latest technologies in sequencing and analytics to harness the power of human genetics to create game changing new medicines."

– Aris Baras, Head of RGC

RGC Milestones

2014 — Regeneron sought to further explore the human genetic code and RGC was born. Launched foundational initiative with Geisinger to sequence 100k participants.

2017 — Discovered inhibition of ANGPTL3 gene in humans and mice is associated with decreased levels of all 3 major lipid fractions and protection from atherosclerotic cardiovascular disease.

2018 — Uncovered loss-of-function variant in HSD17B13 gene associated with reduced risk of chronic liver disease. Partnered with UK Biobank to accelerate our research goals.

2020 — Sequenced our 1,000,000th exome – first organization in the world to do so.

2021 — Discovered rare genetic mutations in GPR75 gene associated with protection against obesity.

2022 — Uncovered a novel association between rare mutations in the CIDEB gene and protection from liver damage and disease.

Science-Led

World-class scientists & researchers.

120+
peer reviewed manuscripts
published by RGC team

1st
genome center in the cloud
with fully automated analysis pipelines

RGC Collaborations

Global network of collaborator institutions.

120+
collaborations

23
countries

The Database

Largest & most diverse in the world.

~2M
exomes sequenced
and counting

500K+
underrepresented
individuals sequenced

Development of Therapeutics

Our mission: genetics to therapeutics, designed for all.

3
genetics medicines
programs in the clinic

20+
additional programs in
research & candidate selection

15+
novel genetic
targets discovered

25+
novel protective
genetics discoveries

Science Obsessed, Human Inspired.